|Articles|October 10, 2017

James McKinnell, MD: Outcomes of Delafloxacin Treatment for Skin Structure Infections

Author(s)Jenna Payesko

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

James McKinnell, MD, David Geffen School of Medicine, UCLA: I think it's really important for doctors in all branches of care to pay attention to novel antibiotics. I think as we learn about antibiotics, we see the weaknesses of old agents and the benefits of new agents and when you're looking at delafloxacin, there's some significant differences compared to other fluoroquinolones. It simply has anti-MRSA activity, it means you can use it for your skin, and the safety profile is different. There's no QT prolongation for delafloxacin that's been observed, and that's a huge advantage for traditional agents particularly in the elderly patient population.

So the safety data being presented at this meeting talks about delafloxacin verses vancomycin and aztreonam, and the overall summary is that the delafloxacin was noninferior to vancomycin aztreonam. There were some differences in discontinuation where delafloxacin was discontinued less frequently than vancomycin, and the side effects are characterized as relatively mild. So, it's encouraging to see what may be a more tolerable agent there.

So this is a very different change from old fluoroquinolones. Again, the idea of that safety factor of no QT prolongation, when especially if you're looking in the elderly patient population where your number needed to harm for a fluoroquinolone from just simply QT prolongation could be 1 in 30 to have an arrhythmia event, to 1 in 500 to have potentially torsades de pointes — to be able to get rid of that, is a major step forward, so that's an encouraging development for fluoroquinolones. And you have to understand the use of this drug, fluoroquinolones are drugs that traditionally been ones that we've tried to avoid for a whole host of reasons, yet there were 3 million fluoroquinolone prescriptions written last year. So here's potentially a safer, different option, that may be tolerable for skin and skin structure infections.

This video originally appeared on MDMag.com.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.